免疫检查点阻滞剂治疗恶性黑色素瘤进展

摘要/Abstract

中图分类号:

R739.8

张湉, 郭伟. 免疫检查点阻滞剂治疗恶性黑色素瘤进展[J]. 中国口腔颌面外科杂志, 2017, 15(4): 377-381.

[1] 郭伟. 头颈肿瘤诊断治疗学[M]. 北京: 人民军医出版社, 2013: 138-148.
[2] Shoo BA, Kashani-Sabet M. Melanoma arising in African-, Asian-, Latino- and Native-American populations[J]. Semin Cutan Med Surg, 2009, 28(2): 96-102.
[3] Mervic L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women [J]. PLoS One, 2012, 7(3): e32955.
[4] Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects [J]. Oncologist, 2011, 16(1): 5-24.
[5] Dudek-Peric AM, Ferreira GB, Muchowicz A, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin[J]. Cancer Res, 2015, 75(8): 1603-1614.
[6] Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer [J]. Nature, 2015, 520(7547): 373-377.
[7] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy [J]. Nat Rev Cancer, 2012, 12(4): 252-264.
[8] Mullard A. New checkpoint inhibitors ride the immunotherapy tsunami [J]. Nat Rev Drug Discov, 2013, 12(7): 489-492.
[9] Fourcade J, Sun Z, Pagliano O, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines [J]. Cancer Res, 2014, 74(4): 1045-1055.
[10] Okazaki T, Okazaki IM, Wang J, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice [J]. J Exp Med, 2011, 208(2): 395-407.
[11] Menon S, Shin S, and Dy G. Advances in cancer immunotherapy in solid tumors [J]. Cancers (Basel), 2016, 8(12): E106.
[12] Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 [J]. Science, 2011, 332(6029): 600-603.
[13] Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase Ⅱ study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage Ⅲ or Ⅳ melanoma [J]. Clin Cancer Res, 2009, 15(17): 5591-5598.
[14] Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study [J]. Lancet Oncol, 2010, 11(2): 155-164.
[15] Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma [J]. N Engl J Med, 2010, 363(8): 711-723.
[16] Yamazaki N, Uhara H, Fukushima S, et al. Phase Ⅱ study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma[J]. Cancer Chemother Pharmacol, 2015, 76(5): 969-975.
[17] Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial [J]. Lancet Oncol, 2015, 16(5): 522-530.
[18] Zimmer L, Eigentler TK, Kiecker F, et al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma [J]. J Transl Med, 2015, 13: 351.
[19] Alexander M, Mellor JD, McArthur G, et al. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma [J]. Med J Aust, 2014, 201(1): 49-53.
[20] Riley JL. PD-1 signaling in primary T cells [J]. Immunol Rev, 2009, 229(1): 114-125.
[21] 许标波, 贺毅憬, 王韦力, 等. 肿瘤免疫检查点抑制剂临床治疗的研究进展[J]. 中国临床药理学与治疗学, 2016, 21(2): 218-224.
[22] Shi L, Chen S, Yang L, et al. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies [J]. J Hematol Oncol, 2013, 6(1): 74.
[23] Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation [J]. J Immunol, 2004, 173(2): 945-954.
[24] Ito A, Kondo S, Tada K, et al. Clinical development of immune checkpoint inhibitors [J]. Biomed Res Int, 2015, 2015: 605478.
[25] Topalian SL, Drake CG, and Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity [J]. Curr Opin Immunol, 2012, 24(2): 207-212.
[26] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer [J]. N Engl J Med, 2012, 366(26): 2443-2454.
[27] Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma [J]. JAMA, 2016, 315(15): 1600-1609.
[28] Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial [J]. Lancet Oncol, 2015, 16(8): 908-918.
[29] Schadendorf D, Dummer R, Hauschild A, et al. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma [J]. Eur J Cancer, 2016, 67: 46-54.
[30] Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial [J]. Lancet Oncol, 2015, 16(4): 375-384.
[31] Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med, 2015, 372(26): 2521-2532.
[32] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma [J]. N Engl J Med, 2015, 373(1): 23-34.

免疫检查点阻滞剂治疗恶性黑色素瘤进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈华, 李婧, 罗梅. 红景天甙通过NRF2/KEAP1通路对口腔鳞癌细胞生长的影响[J]. 中国口腔颌面外科杂志, 2024, 22(5): 424-429.
[2]	何冉, 侯德强. 口腔颌面部肿瘤患者围术期症状群与生活质量相关性研究[J]. 中国口腔颌面外科杂志, 2024, 22(5): 446-454.
[3]	王雪, 张宁. 810 nm波长半导体激光治疗口腔黏液腺囊肿的临床疗效观察[J]. 中国口腔颌面外科杂志, 2024, 22(5): 459-462.
[4]	黄昕, 郭正健, 包刚, 张婷婷. 牙龈软组织外周型成釉细胞瘤1例报告[J]. 中国口腔颌面外科杂志, 2024, 22(5): 510-512.
[5]	茅传青, 林智霖, 刘钰, 蔡志宇, 陈伟辉. 颊部前臂游离皮瓣发生表皮样囊肿1例报告[J]. 中国口腔颌面外科杂志, 2024, 22(5): 518-520.
[6]	赵慧, 舒欣, 张帆, 任伟伟, 刘姣, 朱珠. 基于生物信息学和体外实验筛选头颈鳞癌生物标志物[J]. 中国口腔颌面外科杂志, 2024, 22(4): 329-338.
[7]	郭毅波, 李晨尧, 樊奇, 季彤, 任振虎. 头颈癌治疗诱发的淋巴水肿：临床因素和预后分析[J]. 中国口腔颌面外科杂志, 2024, 22(4): 360-364.
[8]	黄灿, 罗涛, 孙宇. 改良衰弱评估对行口腔鳞癌皮瓣重建术老年患者术后并发症的预测价值[J]. 中国口腔颌面外科杂志, 2024, 22(4): 373-377.
[9]	郭逸飞, 张永红, 任振虎. 头颈部肉瘤的诊断与治疗现状[J]. 中国口腔颌面外科杂志, 2024, 22(4): 404-408.
[10]	李晨曦, 方昌, 龚忠诚, 邵博. 累及颞下颌关节整体结构的软骨黏液样纤维瘤：手术切除及关节重建1例报告[J]. 中国口腔颌面外科杂志, 2024, 22(4): 409-412.
[11]	徐晨, 马丽娟, 石尧, 文玉珍, 宋永海, 车宗刚. 腮腺区炎性肌纤维母细胞瘤1例报告及文献复习[J]. 中国口腔颌面外科杂志, 2024, 22(4): 413-416.
[12]	惠琪, 高万鹏, 李欢, 赵琦, 王珺, 魏建华, 杨新杰, 杨子桧. 唾液腺腺样囊性癌微环境中肿瘤相关巨噬细胞外泌体差异表达miRNAs的筛选及验证[J]. 中国口腔颌面外科杂志, 2024, 22(3): 209-215.
[13]	王睿捷, 马海龙, 张志愿. 组蛋白乳酸化修饰在头颈肿瘤中的表达及意义[J]. 中国口腔颌面外科杂志, 2024, 22(3): 228-232.
[14]	洪磊, 陈伟良. 口腔癌老年患者术后静脉血栓栓塞症的危险因素分析[J]. 中国口腔颌面外科杂志, 2024, 22(3): 233-238.
[15]	王敏, 钱佳骏, 薛俊青, 顾挺, 胡宇华, 陈颖, 夏荣辉. 唾液腺腺泡细胞癌中NR4A3基因重排及NOR-1蛋白表达分析[J]. 中国口腔颌面外科杂志, 2024, 22(3): 249-254.